Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Candel Therapeutics, Inc.
Xencor, Inc.
Incyte Corporation
Calithera Biosciences, Inc
AbbVie
AbbVie
Eli Lilly and Company
Incyte Corporation
Incyte Corporation
Novartis
Stanford University
Bayer
Masonic Cancer Center, University of Minnesota
Novartis
Stanford University
Valerio Therapeutics
Valerio Therapeutics
University of Chicago